The revolutionary Equilia system, meant to treat heart failure, has been successfully implanted for the first time in a clinical study . The developer of the system, Sorin Group, is an Italian medical device company, leader in the treatment of cardiovascular diseases.
Heart failure is a chronic progressive disease in which the heart can no longer pump enough blood to meet the needs of the body. An estimated 22M people in Europe and the US suffer from this disease and associated syndromes such as sleep apnea, cardiac arrhythmia and diabetes. Not only does the disease have low survival rates, but it also generates high hospital costs for the healthcare systems. Moreover, due to their unstable cardiac condition, heart failure patients have a very high hospital readmission rate.
The cardiovascular disease has been shown to be associated with an imbalance in the autonomic nervous system that controls cardiac activity. This imbalance, a reduction in parasympathetic activity and an increase in sympathetic activity, overstresses the heart and contributes to the worsening of heart failure.